Abstract 88P
Background
The WHO Model List of Essential Medicines (EML) serves as guidance for the development of national lists of essential medicines. Since ipilimumab was first approved in 2011, immune checkpoint inhibitors (ICI) have changed the oncologic treatment landscape, leading to significant survival advantages. However, except for malignant melanoma, repeated EML applications of ICIs were unsuccessful and global access remains limited. This study was part of a WHO EML application for the therapeutic class of ICIs in the palliative first-line treatment setting of adult cancers and aims to provide a prioritization framework to select ICIs and indications with the highest potential for EML inclusion.
Methods
After drafting a goal-directed, sequential prioritization plan, the European Medicines Agency’s (EMA) drug database was searched systematically for approved ICI and treatment indications. Next, based on the potential population reach and availability of high-level evidence, ICI-containing treatments approved for the palliative first-line setting were reviewed. Lastly, ESMO-Magnitude of Clinical Benefit Scale (MCBS) scorecards were examined to identify therapeutic indications with a score of 4 or 5, denoting a substantial clinical benefit. ESMO experts will review top-ranked regimens and cancers to complement the evidence about efficacy and harms, judge feasibility and accessibility, and discuss controversial additions.
Results
The EMA drug database search yielded 11 ICIs with 76 different approvals for 21 cancer types and subtypes. Of these, 44 approvals were in the palliative first-line setting. Evaluation against ESMO-MCBS scorecards led to the inclusion of 29 approvals for further evaluation and analysis. Briefing documents for selected cancers and ICIs, with input from ESMO experts, will enhance the transparency and completeness of the EML application to support the WHO Expert committee's selection.
Conclusions
Our research demonstrates the feasibility of using the ESMO-MCBS as part of a framework to identify and prioritise promising ICI-containing treatment regimens for WHO EML application. Therefore, further exploration of the framework as part of the WHO EML application process is warranted.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract